Jubilant Life Sciences Limited wholly-owned subsidiary, Jubilant Pharma Limited has entered into a strategic partnership with SOFIE Biosciences, USA. 

 

Under the terms of the partnership, Jubilant with 25% of equity holding shall be a strategic partner to SOFIE, enabling SOFIE to continue to grow production capacity, advance its theranostic pipeline and support novel PET diagnostic manufacturing and distribution within the US.

 

Strategic partnership between Jubilant and SOFIE will enable them to collaborate in the development, manufacturing and distributions of radio pharmaceuticals that will help in diagnosis and treatment of a wide variety of oncology diseases. 

 

SOFIE’s vision is to improve patient outcomes by developing and delivering molecular diagnostics and therapeutics (Theranostics). With its robust radiopharmaceutical production and distribution network, mature contract manufacturing services, and now, high value Theranostic intellectual property, SOFIE is poised to deliver on the promise of nuclear medicine.

 

The acquisition is planned to be completed by January 2021.